Sign In
Buy ZURA
$4.31
+0.0750 (+1.77%)
At Close: Jun 23, 2026
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Thursday, 14'th May 2026
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfull
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
07:30am, Wednesday, 13'th May 2026
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives o
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
07:30am, Thursday, 07'th May 2026
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives o
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 04'th May 2026
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfu
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Moderate Buy” by Analysts
04:24am, Tuesday, 14'th Apr 2026
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. One analy
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $11.60
01:46am, Monday, 23'rd Mar 2026
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated t
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
04:05pm, Thursday, 19'th Mar 2026
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningful
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully
Zura Bio to Participate in Upcoming Investor Conferences
06:30am, Monday, 02'nd Mar 2026
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medi
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
06:30am, Wednesday, 25'th Feb 2026
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
04:01pm, Tuesday, 24'th Feb 2026
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients wi
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.
06:30am, Monday, 23'rd Feb 2026
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medi
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
05:02am, Tuesday, 17'th Feb 2026
Zura Bio (NASDAQ: ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities' Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispe
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
06:30am, Wednesday, 04'th Feb 2026
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medi
